|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"oh sc"
Showing items 1-13 of 13 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku, N;Omori, T;Shitara, K;Sakuramoto, S;Yamaguchi, K;Kato, K;Kadowaki, S;Tsuji, K;Ryu, MH;Oh, DY;Oh, SC;Rha, SY;Lee, KW;Chung, IJ;Sym, SJ;Chen, LT;Chen, JS;Bai, LY;Nakada, T;Hagihara, S;Makino, R;Nishiyama, E;Kang, YK |
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 國家衛生研究院 |
2021-09-04 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
|
Kang, YK;Morita, S;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Chen, LT;Boku, N |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data
|
Chen, LT;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, W;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N |
| 國家衛生研究院 |
2019-12-20 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, LT;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Kang, YK;Boku, N |
| 國家衛生研究院 |
2019-10 |
A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FO
|
Chen, LT;Hitre, E;Lee, WJ;Bai, LY;Papai, Z;Kang, SY;Dvorkin, M;Choi, HJ;Oh, SC;Artru, P;Bachet, JB |
| 國家衛生研究院 |
2019-05-13 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T;Kang, YK;Chao, Y;Ryu, MH;Kato, K;Cheol Chung, H;Chen, JS;Muro, K;Ki Kang, W;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Tanimoto, M;Chen, LT;Boku, N |
| 國家衛生研究院 |
2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
|
Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Morita, S;Chen, LT;Boku, N |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
| 國家衛生研究院 |
2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
|
Boku, N;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Chen, LT |
| 國家衛生研究院 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
|
Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT |
Showing items 1-13 of 13 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
